Clinical Trial: NCT06799286
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BMS-986489 in Chinese Participants With Relapsed/Refractory Small Cell Lung Cancer
Status:
COMPLETEDPhase:
Phase 1| Lead Sponsor: | Bristol-Myers Squibb |
| Information Provided By: | Bristol-Myers Squibb |
| Last Update Posted: | 2026-09-24 |
Study Overview
Brief Summary
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, and preliminary efficacy of BMS-986489 in Chinese participants with R/R SCLC (Relapsed/Refractory Small Cell Lung Cancer).
Official Title
An Open-label, Single-arm, Multicenter, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) in Chinese Participants With Relapsed/Refractory Small Cell Lung Cancer
Conditions
Small Cell Lung Carcinoma
Intervention / Treatment
- Drug: BMS-986489
Other Study ID Numbers
- CA245-0002
Start Date (Actual)
2025-05-07
Primary Completion Date (Actual)
2026-09-09
Study Completion Date (Actual)
2026-09-09
Enrollment (Actual)
10
Study Type
Interventional
Phase
Phase 1
| Lead Sponsor: | Bristol-Myers Squibb |
| Information Provided By: | Bristol-Myers Squibb |
| Last Update Posted: | 2026-09-24 |
Study Overview
Brief Summary
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, and preliminary efficacy of BMS-986489 in Chinese participants with R/R SCLC (Relapsed/Refractory Small Cell Lung Cancer).
Official Title
An Open-label, Single-arm, Multicenter, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) in Chinese Participants With Relapsed/Refractory Small Cell Lung Cancer
Conditions
Small Cell Lung Carcinoma
Intervention / Treatment
- Drug: BMS-986489
Other Study ID Numbers
- CA245-0002
Start Date (Actual)
2025-05-07
Primary Completion Date (Actual)
2026-09-09
Study Completion Date (Actual)
2026-09-09
Enrollment (Actual)
10
Study Type
Interventional
Phase
Phase 1